Key features and details
- Rabbit polyclonal to HIGD2A
- Suitable for: IHC-P, WB, ICC/IF
- Reacts with: Human
- Isotype: IgG
Product nameAnti-HIGD2A antibody
See all HIGD2A primary antibodies
DescriptionRabbit polyclonal to HIGD2A
Tested applicationsSuitable for: IHC-P, WB, ICC/IFmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse
- WB: HEK-293 whole cell lysates; IHC-P: Human kidney tissue; ICC: MCF7 whole cells.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 0.02
Preservative: 0.02% Sodium azide
Constituents: 59% PBS, 40% Glycerol
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab150893 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/20 - 1/50. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
|WB||Use a concentration of 0.04 - 0.4 µg/ml. Predicted molecular weight: 11 kDa.|
|ICC/IF||Use a concentration of 0.25 - 2 µg/ml.
Fixation/Permeabilization: PFA/Triton X-100
Cellular localizationMembrane; Multi-pass membrane protein
- HIG1 domain family member 2A antibody
- HIG1 hypoxia inducible domain family, member 2A antibody
- Higd2a antibody
Anti-HIGD2A antibody (ab150893) at 0.4 µg/ml + HEK-293 (Human epithelial cell line from embryonic kidney) whole cell lysate
Predicted band size: 11 kDa
Immunohistochemical analysis of human kidney tissue labeling HIGD2A in the granular cytoplasm of cells in tubules with ab150893 at a 1/20 dilution.
Performed heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
Immunocytochemical analysis of MCF7 (Human breast adenocarcinoma cell line) whole cells labeling HIGD2A in the cytosol and mitochondria with ab150893 at 2 µg/ml.
ab150893 has not yet been referenced specifically in any publications.